Advertisement
U.S. markets closed

Eloxx Pharmaceuticals, Inc. (ELOX)

Other OTC - Other OTC Delayed Price. Currency in USD
1.0200+0.0400 (+4.08%)
At close: 01:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9800
Open1.0000
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range1.0000 - 1.1000
52 Week Range0.4000 - 10.9000
Volume1,168
Avg. Volume8,965
Market Cap3.206M
Beta (5Y Monthly)2.76
PE Ratio (TTM)N/A
EPS (TTM)-8.8800
Earnings DateMay 10, 2024 - May 14, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ELOX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Eloxx Pharmaceuticals, Inc.
    Analyst Report: Bristol-Myers Squibb Co.Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology and cardiovascular conditions. The company completed its merger with Celgene in November 2019. BMY shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

    Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) BARCELONA, Spain and W

  • InvestorPlace

    Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor

    While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically, companies go through much anxiety doing whatever they can to stay listed in a major exchange. Once booted, a certain clarity may materialize, leading to a recovery performance. In some sense, delisted enterprises represent the bears biggest nightmare because such organizations don’t have “anything” to lo

  • GlobeNewswire

    Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

    Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved podocyte foot process effacement in all three treated patients by an average of 60% based on blinded biopsy analysis by NIPOKA GmbH Clinical data from Phase 2 study of ELX-02 for Alport Syndrome included in presentations at the American Society of Nephrology (ASN) Kidney Week 2023 Sig